CANCER CACHEXIA. Barry J A Laird Clinician Scientist in Palliative Medicine, University of Edinburgh & European Palliative Care Research Centre
|
|
- Hugo Woods
- 6 years ago
- Views:
Transcription
1 CANCER CACHEXIA Barry J A Laird Clinician Scientist in Palliative Medicine, University of Edinburgh & European Palliative Care Research Centre Consultant in Palliative Medicine BWoSCC and Edinburgh Cancer Centre, UK
2 Acknowledgements University of Edinburgh Prof Ken Fearon, Prof Marie Fallon NTNU Prof P Klepstad, Prof S Kaasa, Prof P Fayers, Prof M Hjermstad University of Glasgow Prof D McMillan
3 Current standard of care in cancer cachexia? What are the licensed treatments for cancer cachexia? Dexamethasone Megesterol
4 A well designed study to evaluate the benefit of nutritional support in patients with weight loss receiving chemotherapy is needed PJ Ross et al 2004
5
6 The relationship between clinic-pathological factors and survival in patients with metastatic lung cancer (n=390) Parameter n % Univariate Multivariate Sex (M/F) 341/ / ( ) Age ( 65/ 65-74/ 74years) 154 /150/ /38.5/ ( ) HR (95% CI) p-value HR (95% CI) p-value Tumour type (NSCLC vs SCLC) 288/ / ( ) Weight loss (%) Category in past 3 months (1/2) a Performance Status (ECOG) (0-1/2/3/4) 195/ / ( ) /75/31/ /19.2/7.9/ ( ) < ( ) <0.001 mgps (0/ 1/ 2) 103/183/ /46.9/ ( ) < ( ) <0.001
7
8 Pathophysiology There have been great advances in the knowledge of cachexia pathophysiology This has lead to an increased understanding that cachexia is a distinct entity and must be treated as such
9 ANABOLIC BLOCKADE Systemic Inflammatory Response Cachexia Anorexia Physical Inactivity
10 Pro-inflammatory NORMAL Anti-inflammatory CANCER CACHEXIA Anti-inflammatory Pro-inflammatory
11 Inflammation & Cancer Inflammation predisposes to certain tumour types Inflammation implicated in oncogenic mutations & experimental animal models of tumour development 1 Inflammation can be a result of cancer. Targeting inflammation can reduce cancer risk and cancer spread. 7 th hallmark of cancer
12
13
14 Why has research in cachexia been slow? Unimodal therapy trials Prerequisite of oncology trials Late phase You are not eligible if you are taking part in another trial fastidious vs pragmatic trials gatekeeping Limited pharmaceutical funding Lack of a consensus definition
15 Volume 12, Issue 5, May 2011, P A multifactorial syndrome characterised by an on-going muscle loss (with or without fat loss) that cannot be fully reversed by nutritional support and leads to progressive functional impairment. The pathophysiology is characterized by a negative protein and energy balance driven by a variable combination of reduced nutritional intake and abnormal metabolism
16 Pre-cachexia Cachexia Refractory-cachexia Death Weight loss <5% Anorexia & metabolic change Weight loss>5% or BMI<20 and weight loss >2% or sarcopenia and weight loss >2% Variable degree of cachexia. Cancer disease both procatabolic and not responsive to anti-cancer treatment. Low PS, survival <3 months
17 Multimodal Therapy: High protein nutrition Anti-inflammatory agents to down regulate the APPR Routine mobilisation programmes to prevent deconditioning and encourage physical activity-induced stimulation of post prandial anabolism. Mantovani G, Maccio A, Madeddu C, et al. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist 2010;15:200-11
18 Multimodal Intervention Critical pre-cachexic phase Combined with anti-cancer therapy
19 premenac Study A multicentre, open, randomized phase II study comparing a multimodal intervention (oral nutritional supplements, celecoxib and physical exercise) for cachexia versus standard cancer care. (EudraCT number: ) Funding EU FP6 framework
20 Identification Consent Treatment Arm (Multimodal intervention + Standard cancer care) Control Arm (Standard cancer care) Week 0 Week 6 Participants are offered same treatment as treatment arm (Multimodal intervention) Week 12
21 Multimodal Intervention (1) - Nutrition Aim: promote energy balance & ensure optimal protein intake Dietician led interview targets set. Information on dietary intake assessed. Advice given to modify diet to achieve targets Oral nutritional supplements 2 cartons (2x 220mls) per day of ProSURE. Contains 1.1g of EPA per carton. Energy and protein dense. Balstad, T.R., et al., Dietary treatment of weight loss in patients with advanced cancer and cachexia: A systematic literature review. Crit Rev Oncol Hematol, Baldwin, C., et al., Oral nutritional interventions in malnourished patients with cancer: a systematic review and meta-analysis. J Natl Cancer Inst, (5): p Cerchietti, L.C., A.H. Navigante, and M.A. Castro, Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer. Nutr Cancer, (1): p
22 Multimodal Intervention (2) - Exercise Aim: to stabilize muscle mass, strength and improve physical performance Physiotherapist initial instruction and assessment Aerobic minimum 2 x 30 minute sessions per week (Borg scale 12-14) Resistance tailored 0.5-5kg weights. 3x20 minute sessions per week. Increasing weight over period of study Stene GB, Helbostad JL, Balstad TR, Riphagen, II, Kaasa S, Oldervoll LM. Effect of physical exercise on muscle mass and strength in cancer patients during treatment--a systematic review. Crit Rev Oncol Hematol
23 Multimodal Intervention (3) - COXII Aim: to target overproduction of inflammatory cytokines Celecoxib most studied, may have beneficial effects in cachexia Dose 300mg per day. Cerchietti, L.C., A.H. Navigante, and M.A. Castro, Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer. Nutr Cancer, (1): p Maccio A, Madeddu C, Gramignano G, et al. A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life. Gynecol Oncol 2012;124: Solheim, T.S., et al., Non-steroidal anti-inflammatory treatment in cancer cachexia: A systematic literature review. Acta Oncol, 2012.
24 Endpoints Primary Feasibility, recruitment, retention Secondary LBM, weight, activity, nutritional, toxicity, anti-cancer therapy
25 Antiinflammatories Systemic Inflammatory Response Nutritional Intake Cachexia Exercise Anorexia Immunomodulation! Physical Inactivity
26 Cachexia treatment hierarchy 1. Anti-neoplastic therapy 2. Target inflammation 3. Target factors affecting food and activity 4. Optimise nutritional intake 5. Promote activity
27
Dr Barry Laird Clinician Scientist in Palliative Medicine University of Edinburgh and the European Palliative Care Research Centre (PRC)
1 Dr Barry Laird Clinician Scientist in Palliative Medicine University of Edinburgh and the European Palliative Care Research Centre (PRC) 2 Acknowledgements Prof Marie Fallon (group lead EPAS) University
More informationMultimodal cachexia management
Multimodal cachexia management Dr Martin Chasen MBChB FCP(SA) MPhil(Pall Care) Medical Oncologist/Director of Palliative care William Osler Health Services Toronto CANADA Do you have anything that you
More informationESPEN Congress Geneva 2014 LLL LIVE COURSE: NUTRITIONAL SUPPORT IN CANCER. Multimodal therapy of cancer cachexia K. Fearon (UK)
ESPEN Congress Geneva 2014 LLL LIVE COURSE: NUTRITIONAL SUPPORT IN CANCER Multimodal therapy of cancer cachexia K. Fearon (UK) Multimodal therapy for cancer cachexia KCH Fearon Learning objectives Understand
More informationNutritional requirements in advanced cancer patients
Nutritional requirements in advanced cancer patients Paula Ravasco p.ravasco@fmedicina.ulisboa.pt Laboratory of Nutrition Faculty of Medicine of the University of Lisbon Medical School of Lisbon Portugal
More informationNutritional Support in Cancer Topic 26
Nutritional Support in Cancer Topic 26 Module 26.3 Multimodal Therapy for Cancer Cachexia Kenneth Fearon, MD, FRCS(Glas), FRCS(Ed), FRCS(Eng), Professor of Surgical Oncology, Clinical Surgery, University
More informationThe use of omega-3 fatty acids in the management of cancer cachexia. Rhys White Principal Oncology Dietitian Guys and St Thomas NHS Foundation Trust
The use of omega-3 fatty acids in the management of cancer cachexia Rhys White Principal Oncology Dietitian Guys and St Thomas NHS Foundation Trust Overview Cancer cachexia Clinical features Pathogenesis
More informationESPEN guidelines: Nutritional interventions in advanced cancer care. -An overview and pending research questions
1 ESPEN guidelines: Nutritional interventions in advanced cancer care -An overview and pending research questions Tora Skeidsvoll Solheim, MD, PhD Oslo, October 2017 2 3 Definition of cachexia Cancer cachexia
More informationTHE UNIVERSITY of EDINBURGH
THE UNIVERSITY of EDINBURGH Professor Kenneth Fearon MB ChB(Hons), MD, FRCPS (Glasgow), FRCS (Edinburgh), FRCS (England) Memorial Cancer Cachexia Symposium Royal Society of Edinburgh, George Street, Edinburgh
More informationA randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer
Journal of Cachexia, Sarcopenia and Muscle (2017) Published online in Wiley Online Library (wileyonlinelibrary.com) ORIGINAL ARTICLE A randomized phase II feasibility trial of a multimodal intervention
More informationCancer cachexia: assessment and classification. KCH Fearon University of Edinburgh Scotland
Cancer cachexia: assessment and classification KCH Fearon University of Edinburgh Scotland 1 What is the cancer cachexia phenotype?...the shoulders, clavicles, chest and thighs melt away. This illness
More informationHorizon Scanning Centre November Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer first line
Horizon Scanning Centre November 2012 Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer first line SUMMARY NIHR HSC ID: 5206 This briefing is based on information available
More informationNutrition support for sarcopenia in cancer patients
Nutrition support for sarcopenia in cancer patients Kalliopi Anna Poulia, RD, MMedSci, PhD Clinical Nutritionist-Dietitian, Laiko General Hospital of Athens Vice President of the Hellenic Dietetic Association
More informationA new era of therapeutics for cancer cachexia. Cachexia is a continuum with 3 stages of clinical relevance
A new era of therapeutics for cancer cachexia I. Depletion of Reserves II. Limitation of food intake III. Catabolic Drivers IV. Impact and outcomes Vickie Baracos PhD Professor and Alberta Cancer Foundation
More informationClassification of (cancer) cachexia: Any improvements to expect?
6 th Research Congress of EAPC Glasgow, June 11th 2010 Session Cachexia of EPCRC and EAPC RN Classification of (cancer) cachexia: Any improvements to expect? The joint work of many persons involved, thank
More informationNutritional Support in Cancer
Nutritional Support in Cancer Topic 26 Module 26.4 Pharmacological and Multimodal Therapy for Cancer Cachexia Learning Objectives Ingvar Bosaeus Kenneth Fearon Grant Stewart Comprehend the importance of
More informationCombination therapy in cachexia
Review Article Combination therapy in cachexia Egidio Del Fabbro Virginia Commonwealth University, Richmond, VA, USA Correspondence to: Egidio Del Fabbro, MD. Virginia Commonwealth University, 1101 E Marshall
More informationThe Challenge of Cancer Cachexia
The Challenge of Cancer Cachexia Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Director, Solid Tumor Therapeutics Program Duke Cancer Institute Disclosures Advisory Board/Consultant:
More informationSingle Technology Appraisal (STA) Anamorelin for treating cachexia and anorexia in people with non-small-cell lung cancer
Single Technology Appraisal (STA) Anamorelin for treating cachexia and anorexia in people with non-small-cell Response to consultee and commentator comments on the draft remit and draft scope (pre-referral)
More informationMetabolic issues in nutrition: Implications for daily care
Metabolic issues in nutrition: Implications for daily care Ingvar Bosaeus Dept of Clinical Nutrition Sahlgrenska University Hospital Göteborg, Sweden Nutritional problems in cancer In western countries,
More informationIntegration of Palliative and Oncology Care in patients with lung and other
1 Integration of Palliative and Oncology Care in patients with lung and other thoracic cancer: referral criteria and clinical care pathways. A. Caraceni, C. Brunelli, S. Lo Dico, E. Zecca, P. Bracchi,
More informationIngvar Bosaeus, MD, Sahlgrenska University Hospital, Goteborg, Sweden
Cachexia in Cancer Ingvar Bosaeus, MD, Sahlgrenska University Hospital, Goteborg, Sweden Severe, progressive malnutrition and wasting often is seen in advanced cancer, with weight loss long associated
More informationMolecular Mechanisms associated with the Cancer-Cachexia Syndrome
Molecular Mechanisms associated with the Cancer-Cachexia Syndrome Prof. Dr. Josep M. Argilés Department of Biochemistry & Molecular Biology University of Barcelona, Spain Disclosures: DANONE (Scientific
More informationCancer Cachexia. Current and Future Management Options
Cancer Cachexia Current and Future Management Options Cancer Cachexia Overview Symptoms Pathophysiology Current Treatment Options New Drugs Cancer Cachexia Overview " the shoulders, clavicles, chest and
More informationONO PHARMACEUTICAL CO., LTD. Corporate Communications
September 29, 2014 ONO PHARMACEUTICAL CO., LTD. Corporate Communications public_relations@ono.co.jp Helsinn Group, Switzerland, announced the results of Phase III Trials (ROMANA 1 and ROMANA 2) of Anamorelin/ONO-7643
More informationBAOJ Palliative medicine
Vol:, Issue: Abstract Randomised Controlled Trial of Fish Oil Supplement to Treat Cancer Cachexia Dewey A, Higgins B, Baughan C, Stores R, 4 Dean T, Sally Kilburn School of Health Sciences and Social Work,
More informationProSure. Strength to Fight and Get Back to Life. Strength to Fight and Get Back to Life D1
ProSure Strength to Fight and Get Back to Life ProSure. Strength to Fight and Get Back to Life 5004 1112 166 D1 Cancer care is evolving at an incredibly fast pace, and the prognosis for a person with cancer
More informationPrognostication in Advanced Cancer: A Study Examining an Inflammation-Based Score
Vol. 44 No. 2 August 2012 Journal of Pain and Symptom Management 161 Original Article Prognostication in Advanced Cancer: A Study Examining an Inflammation-Based Score Michael Partridge, MBChB, Marie Fallon,
More informationTITLE: Nutritional Supplementation for Patients with Cancer: A Review of the Clinical Effectiveness and Guidelines
TITLE: Nutritional Supplementation for Patients with Cancer: A Review of the Clinical Effectiveness and Guidelines DATE: 12 February 2014 CONTEXT AND POLICY ISSUES People with cancer who are well nourished
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Abiraterone for the treatment of metastatic castration-resistant prostate cancer that has progressed on or after a docetaxel-based chemotherapy regimen Disease
More informationMalnutrition in advanced CKD
Malnutrition in advanced CKD Malnutrition Lack of proper nutrition, caused by not having enough to eat, not eating enough of the right things or being unable to use the food that one does eat Jessica Stevenson
More informationDiet what helps? Lindsey Allan Macmillan Oncology Dietitian Royal Surrey County Hospital, Guildford
Diet what helps? Lindsey Allan Macmillan Oncology Dietitian Royal Surrey County Hospital, Guildford Diet and cancer Diet and cancer Nutrition research Lack of funding RCTs Low quality Small sample sizes
More informationAmerican Journal of Clinical Nutrition July, 2004;80:204 16
1 Dietary intake of n 3 and n 6 fatty acids and the risk of prostate Cancer American Journal of Clinical Nutrition July, 2004;80:204 16 Michael F Leitzmann, Meir J Stampfer, Dominique S Michaud, Katarina
More informationClinical Nutrition in the 21st Century Malnutrition, sarcopenia and cachexia
Clinical Nutrition in the 21st Century Malnutrition, sarcopenia and cachexia Stéphane M. Schneider, MD, PhD, FEBGH Professor of Nutrition and ESPEN ECPC Chair In proto-indo-european, Latin and Greek Under
More information1st Abbott International Conference for Cancer Nutrition Therapy. Proceedings Booklet
1st Abbott International Conference for Cancer Nutrition Therapy Proceedings Booklet The 1st Abbott International Conference for Cancer Nutrition Therapy April 12-14, 2010 The 1st Abbott International
More informationIntegration of palliative care into oncology
1 Integration of palliative care into oncology Stein Kaasa European Palliative Care Research Centre, Faculty of Medicine, NTNU and Department of Oncology, St. Olavs Hospital, Trondheim University Hospital
More informationAlterazioni metaboliche e nutrizionali in corso di artrite reumatoide e malattie autoimmuni Alessio Molfino, MD, PhD
Alterazioni metaboliche e nutrizionali in corso di artrite reumatoide e malattie autoimmuni Alessio Molfino, MD, PhD Direttore: Prof. Filippo Rossi Fanelli alessio.molfino@uniroma1.it Rheumatoid arthritis
More informationDeveloping your Integrative Self-Care Plan
Developing your Integrative Self-Care Plan Erin Sweet ND, MPH, FABNO Assistant Research Scientist Bastyr University [PRESENTER PHOTO] Naturopathic Oncology Red Cedar Wellness Center & Orion Center for
More informationSyed H Jafri 1,2*, Runhua Shi 1,2 and Glenn Mills 1,2
Jafri et al. BMC Cancer 2013, 13:158 RESEARCH ARTICLE Open Access Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer
More informationInterprofessional Webinar Series
Interprofessional Webinar Series Management of Anorexia/Cachexia Ebtesam Ahmed, Pharm.D., M.S. Director of Pharmacy Internship MJHS Institute for Innovation in Palliative Care Associate Clinical Professor
More informationCabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer second line after docetaxel
Cabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer second line after docetaxel April 2009 This technology summary is based on information available at the time of research and a
More informationLeveraging Prospective Cohort Studies to Advance Colorectal Cancer Prevention, Treatment and Biology
Leveraging Prospective Cohort Studies to Advance Colorectal Cancer Prevention, Treatment and Biology Charles S. Fuchs, MD, MPH Director, Yale Cancer Center Physician-in-Chief, Smilow Cancer Hospital New
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationRandomised phase III clinical trial of 5 different arms of treatment on 332 patients with cancer cachexia
European Review for Medical and Pharmacological Sciences Randomised phase III clinical trial of 5 different arms of treatment on 332 patients with cancer cachexia G. MANTOVANI Department of Medical Oncology,
More informationNon-small cell lung cancer (NSCLC) remains the commonest
Original Article Clinical Utility of the Pretreatment Glasgow Prognostic Score in Patients with Advanced Inoperable Non-small Cell Lung Cancer Elaine Y.L. Leung, MB ChB,* Hazel R. Scott, MD, and Donald
More informationCancer Cachexia: Beyond Weight Loss
Clinical Review Cancer Cachexia: Beyond Weight Loss Andrew R. Bruggeman, MD, Arif H. Kamal, MD, Thomas W. LeBlanc, MD, Joseph D. Ma, PharmD, Vickie E. Baracos, PhD, and Eric J. Roeland, MD University of
More informationPharmacological treatments. Jann Arends Tumor Biology Center Freiburg, Germany
Pharmacological treatments Jann Arends Tumor Biology Center Freiburg, Germany Pharmacologic treatment: Basic concept Interfere with undesired physiology Drug a specific target Major problems in cachexia
More informationThemes. Evaluer (defini:on, diagnos:c criteria) Recherche clinique en cancérologie : quid du statut nutri:onnel? Agir Adapter 03/04/15
Recherche clinique en cancérologie : quid du statut nutri:onnel? Pierre Senesse, Laboratoire Epsylon, Ins:tut Régional du Cancer de Montpellier SIRIC Vickie Baracos, Department of Oncology, University
More informationBackground 1. Comparative effectiveness of nintedanib
NCPE report on the cost effectiveness of nintedanib (Vargatef ) in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung
More informationOmega-3 supplementation promotes key anti-inflammatory pathways that naturally support back, neck, and joint health and mobility
n Promotes key anti-inflammatory pathways n Promotes joint mobility and flexibility n Is a natural adjunct to conventional therapies n Is safe for long-term use Omega-3 supplementation promotes key anti-inflammatory
More informationFROM ABSTRACT Patients with rheumatoid arthritis (RA) improve on a vegetarian diet or supplementation with fish oil.
Anti-inflammatory effects of a low arachidonic acid diet and fish oil in patients with rheumatoid arthritis Rheumatol Int (2003) 23: 27 36 Olaf Adam, Corinna Beringer, Thomas Kless, Christa Lemmen, Alexander
More informationThe role of omega-3 fatty acids as a treatment for bipolar disorder
The role of omega-3 fatty acids as a treatment for bipolar disorder Research into omega-3 fatty acids as a possible treatment for mood disorders is a new and interesting area of research Although research
More informationThere is more scientific evidence behind the cardiovascular benefits of fish oil than nearly any other nutritional supplement
n Provides optimal support for heart health n Reduces triglyceride levels n Reduces cardiovascular risk factors 7, 8 n Complements statin drug therapy n Optimizes circulation and blood vessel function
More informationBasic pathophysiology of recovery: the role of endocrine metabolic response. Franco Carli McGill University Montreal, Canada
Basic pathophysiology of recovery: the role of endocrine metabolic response Franco Carli McGill University Montreal, Canada ASER, Washington, 2016 postoperative recovery, 1950 Loss of body weight, less
More informationCancer Anorexia Cachexia Syndrome
Cancer Anorexia Cachexia Syndrome John Mulder, MD Chief Medical Consultant for Hospice and Palliative Care Holland Home Medical Director, Trillium Institute Grand Rapids, MI Cancer Cachexia - Definitions
More informationLeandro C.A. Cerchietti, Alfredo H. Navigante, and Monica A. Castro
NUTRITION AND CANCER, 59(1), 14 20 Copyright C 2007, Lawrence Erlbaum Associates, Inc. Effects of Eicosapentaenoic and Docosahexaenoic n-3 Fatty Acids From Fish Oil and Preferential Cox-2 Inhibition on
More informationInnovations in Nutritional Therapy for Cats with CKD Rebecca Mullis, DVM, DACVN
Innovations in Nutritional Therapy for Cats with CKD Rebecca Mullis, DVM, DACVN Content presented at the 2017 Hill s Global Symposium in Washington D.C., May 5-6, 2017. Chronic kidney disease (CKD) is
More informationLifestyle Factors and Cancer Survivorship: Observational Findings of Weight, Physical Activity, and Diet on Survival
Lifestyle Factors and Cancer Survivorship: Observational Findings of Weight, Physical Activity, and Diet on Survival Melinda L. Irwin, PhD, MPH Associate Professor of Epidemiology Yale School of Medicine
More informationUniversity of Cagliari, Cagliari, Italy
The Oncologist Symptom Management and Supportive Care Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer Cachexia GIOVANNI MANTOVANI, a ANTONIO MACCIÒ,
More informationPhysical activity, Obesity, Diet and Colorectal Cancer Prognosis. Jeffrey Meyerhardt, MD, MPH Dana-Farber Cancer Institute Boston, MA
Physical activity, Obesity, Diet and Colorectal Cancer Prognosis Jeffrey Meyerhardt, MD, MPH Dana-Farber Cancer Institute Boston, MA Colorectal Cancer Incidence ~148,000 cases in US annually and ~50,000
More informationRenal cachexia. Professor Joanne Reid
Renal cachexia Professor Joanne Reid Cachexia Cachexia is a complex metabolic syndrome associated with underlying illness and characterised by muscle loss, with or without loss of fat Definition of cachexia
More informationNutrition and oncology: medical aspects. Case history. What is cancer? Head, Palliative Care RPAH/Sydney Cancer Centre May 2008
utrition and oncology: medical aspects? Clin Assoc Prof. Paul Glare, FRACP Head, Palliative Care RPAH/Sydney Cancer Centre May 2008 Case history What is cancer? 24M PH IDU, HCV 1/08: bowel obstruction:
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationABC of palliative care: Anorexia, cachexia, and nutrition
BMJ 1997;315:1219-1222 (8 November) Clinical review ABC of palliative care: Anorexia, cachexia, and nutrition Eduardo Bruera Top Does the patient have... Why is the patient... Cachexia is a complex syndrome
More informationPharmacological management of cachexia in adult cancer patients: a systematic review of clinical trials
Advani et al. BMC Cancer (2018) 18:1174 https://doi.org/10.1186/s12885-018-5080-4 RESEARCH ARTICLE Open Access Pharmacological management of cachexia in adult cancer patients: a systematic review of clinical
More informationInfographic (right): ESMO 2014 record breaking Congress
ESMO 2014 Congress Scientific Meeting Report Supportive and Palliative Care Extract 26-30 September 2014 Madrid, Spain Summary The European Society for Medical Oncology (ESMO) Congress, held September
More informationTPN and lipid. RCT of 57 patients. TPN with lipid vs TPN without lipid. TPN associated with increased infectious complications
TPN and lipid RCT of 57 patients TPN with lipid vs TPN without lipid TPN associated with increased infectious complications * * * * Battistella FD, et al. J Trauma 1997; 43:52. Data Needed 1. New TPN trials
More informationAre palliative cancer patients willing and able to participate in a physical exercise program?
Palliative and Supportive Care ~2005!, 3, 281 287. Printed in the USA. Copyright 2005 Cambridge University Press 1478-9515005 $16.00 DOI: 10.10170S1478951505050443 Are palliative cancer patients willing
More informationESPEN Congress Leipzig 2013
ESPEN Congress Leipzig 2013 Nutrition and cancer: impact on outcome Survival, quality of life, reduced toxicity: what can be achieved in cancer patients? M.A.E. van Bokhorst - de van der Schueren (NL)
More informationO ρόλος της διατροφής κατά τη θεραπεία του καρκίνου
O ρόλος της διατροφής κατά τη θεραπεία του καρκίνου I. Gioulbasanis MD, PhD Dept. of Chemotherapy Larissa General Clinic E. Patsidis INTRODUCTION Καρκινογένεση Ενεργός Νόσος Επιβιώσαντες με καρκίνο (cancer
More informationProgramme overview (subject to change)
Programme overview (subject to change) Time 0800-0900 Premiminary programme - Thursday 7 June Olavshallen 1204 seats Olav Tryggvasson 325 seats Haraldsalen 140 seats Tavern/ Brattøra 210 seats 0900-1100
More informationY A L E S C H O O L O F M E D I C I N E. This is a CME accredited activity. The presenters and there are no conflicts of interest.
This is a CME accredited activity. The presenters and there are no conflicts of interest. Pain in Pancreatic Cancer More than 50% of patients with pancreatic cancer suffer from abdominal and back pain
More informationESPEN Congress The Hague 2017
ESPEN Congress The Hague 2017 Altering lifestyle to improve nutritional status in older adults Nutritional interventions to prevent and treat frailty F. Landi (IT) Nutritional interventions to prevent
More informationCase 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First?
Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First? Marc Peeters, MD, PhD Head of the Oncology Department Antwerp University Hospital Antwerp, Belgium marc.peeters@uza.be 71-year-old
More informationrisks. Therefore, perc agreed that the reimbursement criteria should match the eligibility criteria of the SELECT trial.
risks. Therefore, perc agreed that the reimbursement criteria should match the eligibility criteria of the SELECT trial. perc considered input from one patient advocacy group indicating that patients value
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationDiet in cancer. When good cells go bad
Diet in cancer When good cells go bad What is cancer? Cancer means Crab for the creeping way in which it spreads It is a general term for more than 100 types of malignant neoplastic disease Cancer not
More informationNICE Quality Standards and COF
NICE Quality Standards and COF David Baldwin Consultant Respiratory Physician NUH Hon Senior Lecturer Nottingham University Clinical lead NICE lung cancer GL Chair NICE QS Topic Expert Group Quality Standards
More informationCachexia. Disease settings. Mechanism. From Wikipedia, the free encyclopedia
Cachexia From Wikipedia, the free encyclopedia Cachexia (/kəkɛksiə/; from Greek κακός kakos "bad" and ἕξις hexis "condition") [1] or wasting syndrome is loss of weight, muscle atrophy, fatigue, weakness,
More informationPrognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. Bruno Vincenzi Università Campus Bio-Medico di Roma
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients Bruno Vincenzi Università Campus Bio-Medico di Roma Colorectal cancer 3 rd most common cancer worldwide Approximately
More informationA Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia
A Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia Gaurav Bahl, Karl Tennessen, Ashraf Mahmoud-Ahmed, Dorianne Rheaume, Ian Fleetwood,
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationNutritional support in multimodal therapy for cancer cachexia
Support Care Cancer (2008) 16:447 451 DOI 10.1007/s00520-007-0388-7 REVIEW ARTICLE Nutritional support in multimodal therapy for cancer cachexia Ingvar Bosaeus Received: 27 June 2007 / Accepted: 5 December
More informationCetoleic acid makes pelagic fish more healthy
Cetoleic acid makes pelagic fish more healthy WORKSHOP IN FISHMEAL AND FISH OIL, NOVEMBER 2018 Bente Ruyter Nofima Omega-3 fatty acids and health Eye Brain Cell membrane The marine omega-3 fatty acids
More informationScientific Product Rationale
Scientific Product Rationale Supportan & Supportan DRINK Enteral Nutrition Formula Adapted to the Special Needs of Cancer Patients Tube & Sip Feed for Supplemental or Complete Nutrition Food for Special
More informationBreast SSG Education Event Anglia Cancer Network Sally Donaghey Macmillan AHP Lead
Breast SSG Education Event Anglia Cancer Network 10.2.2012 Sally Donaghey Macmillan AHP Lead sally.donaghey@suffolk.pct.nhs.uk IPx People affected by cancer need information that is timely, relevant, and
More informationProphylactic Cranial Irradiation and Thoracic Radiotherapy in Extensive Stage Small-Cell Lung Cancer
Prophylactic Cranial Irradiation and Thoracic Radiotherapy in Extensive Stage Small-Cell Lung Cancer Dr Neil Bayman Consultant Clinical Oncology ESMO-Christie Preceptorship Programme in Lung Cancer, March
More informationPROGESTINS AHFS 68:32
PROGESTINS AHFS 68:32 Class: Sex hormones. Indications: Hormone therapy in breast (megestrol), renal (medroxyprogesterone) and endometrial cancers, anorexia and cachexia (megestrol), postcastration hot
More informationstatus should be eligible for treatment with atezolizumab. perc acknowledged the small number of patients with an EGFR or ALK mutation positive disease recruited on the trials but agreed that the overall
More informationAnaemia & Cancer. John de Vos Consultant Haematologist RSCH
Anaemia & Cancer John de Vos Consultant Haematologist RSCH overview Definitions & setting the scene Causes Consequences Biology Treatment Personal approach Patient Clinical team Anaemia - Definition :
More informationBackground Comparative effectiveness of nivolumab
NCPE report on the cost effectiveness of nivolumab (Opdivo ) for the treatment of locally advanced or metastatic squamous non-small cell lung cancer after prior chemotherapy in adults. The NCPE has issued
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Update on high dose imatinib for gastrointestinal stromal tumour (GIST) harbouring KIT exon 9 mutations
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Update on high dose imatinib for gastrointestinal stromal tumour (GIST) harbouring KIT exon 9 mutations Summary Date prepared: May 2012 Imatinib was the first
More informationName of Policy: Measurement of Long-Chain Omega-3 Fatty Acids in Red Blood Cell Membranes as a Cardiac Risk Factor
Name of Policy: Measurement of Long-Chain Omega-3 Fatty Acids in Red Blood Cell Membranes as a Cardiac Risk Factor Policy #: 239 Latest Review Date: July 2010 Category: Laboratory Policy Grade: Active
More informationSection Editor Steven T DeKosky, MD, FAAN Kenneth E Schmader, MD
Prevention of dementia Author Daniel Press, MD Michael Alexander, MD Section Editor Steven T DeKosky, MD, FAAN Kenneth E Schmader, MD Deputy Editor Janet L Wilterdink, MD Last literature review version
More informationPACLitaxel Monotherapy 80mg/m 2 7 days
INDICATIONS FOR USE: PACLitaxel Monotherapy 80mg/m 2 7 days INDICATION ICD10 Regimen Code *Reimbursement Status Treatment of metastatic breast carcinoma (mbc) in patients C50 00226a Hospital who have either
More informationDr Ahmad Shaltut Othman Anaesthesiologist & Intensivist Hosp Sultanah Bahiyah Alor Setar
FEEDING WITH FISH OIL Dr Ahmad Shaltut Othman Anaesthesiologist & Intensivist Hosp Sultanah Bahiyah Alor Setar New horizons in clinical nutrition from Support to Therapy Landmarks in Parenteral Nutrition
More informationNutritional Support in the Perioperative Period
Nutritional Support in the Perioperative Period Topic 17 Module 17.3 Nutritional Support in the Perioperative Period Ken Fearon Learning Objectives Understand the principles behind nutritional care for
More informationNew targets in endometrial and ovarian cancer
New targets in endometrial and ovarian cancer SAMO Interdisciplinary Workshop on Gynecologic Tumors Luzern, January 16-17, 2016 C. Sessa IOSI Bellinzona Outline New targets in ovarian cancer - Cell cycle
More informationInternational Graduate Course in Exercise & Clinical Physiology
International Graduate Course in Exercise & Clinical Physiology Exercise and Cancer A view to the future through the eyes of the past Robert D. Kilgour, Ph.D., FACSM Professor & Chair Department of Exercise
More informationSarcopenia - a Regulatory Perspective
Sarcopenia - a Regulatory Perspective Dragos Roman, M.D. Team Leader Division of Metabolism and Endocrinology Products, Office of New Drugs, Center for Drug Evaluation and Research, FDA May 11, 2012 1
More information